Meningococcal Infections: all 243 studies
Page 3 of 3. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Investigating Meningococcal Vaccines in AdultsCompletedNCT02398396Not applicable
- Septic cArdiac Deficiency and MenIngococcal seveRe SepsisCompletedNCT02041663Not applicable
- Testing the Use of Prompts to Increase Adolescent Immunization RatesCompletedNCT01984125Not applicable
- Hepatitis B Vaccination in InfantsCompletedNCT01896596Phase 4
- N. Meningitidis Carriage StudyCompletedNCT01808365
- Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate VaccinesCompletedNCT01782066Phase 1/2
- Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and OlderWithdrawnNCT01705379
- MenPF-1 - A New Vaccine Against Meningococcal DiseaseCompletedNCT01640652Phase 1
- Understanding the Immune Response to Two Different Meningitis VaccinesCompletedNCT01593514Phase 4
- Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for MeningitisCompletedNCT01482052Phase 1
- Safety of MenACWY-CRM Vaccination in AdolescentsCompletedNCT01452464
- Safety Surveillance of MenACWY-CRM Vaccine in ChildrenCompletedNCT01452438
- A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and NigerWithdrawnNCT01303211
- Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in AdolescentsCompletedNCT01210885Phase 2
- Correlation Between Cytokines and the Severity of Meningococcal DiseaseCompletedNCT01133834
- Can we Reduce the Number of Vaccine Injections for Children?CompletedNCT01129518Phase 4
- Regulation of Mucosal Immune Response to Systemic MenB VaccineCompletedNCT00774384Phase 2
- Evaluation of Vaccination Reminder/Recall Systems for Adolescent PatientsCompletedNCT00715234Not applicable
- Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in ToddlersCompletedNCT00631995Phase 1
- Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of LifeCompletedNCT00625677Phase 4
- Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same TimeCompletedNCT00581035Phase 4
- B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk FactorsTerminatedNCT00465582
- Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal InfectionCompletedNCT00450632
- Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612CompletedNCT00390143Phase 2
- Persistence of Antibody Response to N. Meningitidis Group C in ChildrenCompletedNCT00316654Phase 4
- Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy ChildrenCompletedNCT00311415Phase 3
- Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC VaccineCompletedNCT00310713Phase 4
- Kinetics of B Cell Response in Infants Menjugate VaccinationCompletedNCT00310700Phase 4
- Persistence of Immune Response After Vaccination With MCCCompletedNCT00310687Phase 4
- Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of AgeCompletedNCT00310674Phase 3
- Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of AgeCompletedNCT00310635Phase 4
- Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy AdolescentsCompletedNCT00297817Phase 2
- Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide VaccineCompletedNCT00271479Phase 4
- Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal VaccineStatus unknownNCT00262015Phase 4
- Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 YrsCompletedNCT00227422Phase 4
- Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate VaccinesCompletedNCT00197808Phase 4
- Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 YrsCompletedNCT00196963Phase 2
- Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 YearsCompletedNCT00196950Phase 2
- Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 YrsCompletedNCT00137917Phase 2
- Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy ToddlersCompletedNCT00135564Phase 2
- Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in InfantsCompletedNCT00135486Phase 2
- Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate VaccineCompletedNCT00126984Phase 2
- Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 YrsCompletedNCT00126945Phase 2